|
ANO6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.33066907387547E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.47569742484188E-11 |
| Normal-vs-Stage2 |
5.661700E-03 |
| Normal-vs-Stage3 |
1.54873000000055E-05 |
| Normal-vs-Stage4 |
2.201000E-04 |
| Stage1-vs-Stage2 |
7.184400E-01 |
| Stage1-vs-Stage3 |
3.784800E-01 |
| Stage1-vs-Stage4 |
2.702200E-01 |
| Stage2-vs-Stage3 |
8.340000E-01 |
| Stage2-vs-Stage4 |
7.150800E-01 |
| Stage3-vs-Stage4 |
8.045400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62492241884138E-12 |
| Normal-vs-AfricanAmerican |
1.521510E-02 |
| Normal-vs-Asian |
5.561000E-03 |
| Caucasian-vs-AfricanAmerican |
6.959400E-01 |
| Caucasian-vs-Asian |
8.778200E-01 |
| AfricanAmerican-vs-Asian |
8.625600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.00429999999796E-06 |
| Normal-vs-Female |
1.668998272919E-12 |
| Male-vs-Female |
9.147600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.40189999900898E-08 |
| Normal-vs-Age(41-60Yrs) |
2.24569995932455E-09 |
| Normal-vs-Age(61-80Yrs) |
1.809580E-04 |
| Normal-vs-Age(81-100Yrs) |
2.424400E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.954600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.188400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.399400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.084000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.808400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.925400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.536500E-02 |
| Classical-VS-Follicular |
1.775630E-03 |
| Classical-VS-Other |
6.200200E-01 |
| Classical-VS-Normal |
1.11022302462516E-16 |
| Tall-VS-Follicular |
1.643250E-01 |
| Tall-VS-Other |
9.572200E-01 |
| Tall-VS-Normal |
4.06490000000037E-05 |
| Follicular-VS-Other |
5.817400E-01 |
| Follicular-VS-Normal |
6.864400E-02 |
| Other-VS-Normal |
3.148000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.57919999965728E-07 |
| Normal-vs-N1 |
8.698300E-03 |
| N0-vs-N1 |
4.328800E-01 |
|
|
